Literature DB >> 8513440

p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis.

G Casey1, Y Yamanaka, H Friess, M S Kobrin, M E Lopez, M Buchler, H G Beger, M Korc.   

Abstract

Pancreatic expression of the p53 tumor suppressor gene was studied in pancreatic adenocarcinomas and chronic pancreatitis. By immunohistochemistry, 16 of 34 (47%) cancers and none of the 24 chronic pancreatitis samples revealed nuclear staining. Sequence analysis indicated that 8 of 24 (33%) cancers were mutated for the p53 gene. Point substitutions occurred at codons 35, 105, 133, 213, 213, 258, and 299. A three base-pair in-frame insertion was identified between codons 261 and 262. None of 8 chronic pancreatitis samples exhibited p53 gene mutations. These data support a role for p53 gene alterations in human pancreatic cancer, and suggest that loss of its regulatory functions may constitute one of the differences between pancreatic cancer and chronic pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513440     DOI: 10.1016/0304-3835(93)90168-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  41 in total

Review 1.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

3.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

4.  Detection of oncogenes in chronic pancreatitis.

Authors:  D Paramythiotis; J Kleeff; J Schmidt; M W Büchler; H Friess
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 5.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

Review 6.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

7.  Overexpression of platelet-derived growth factor (PDGF) B chain and type beta PDGF receptor in human chronic pancreatitis.

Authors:  M Ebert; H U Kasper; S Hernberg; H Friess; M W Büchler; A Roessner; M Korc; P Malfertheiner
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

8.  Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking.

Authors:  E U Lee; M L Cibull; E O'Daniel-Pierce; W E Strodel; C D Jennings
Journal:  Int J Pancreatol       Date:  1995-06

9.  p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.

Authors:  De-Qing Mu; Guo-Feng Wang; Shu-You Peng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.

Authors:  P Laurent-Puig; R Lubin; S Semhoun-Ducloux; G Pelletier; C Fourre; M Ducreux; M J Briantais; C Buffet; T Soussi
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.